Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × Pan-tumor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 273 Carcinoma, Non-Small-Cell Lung 258 Prostatic Neoplasms 150 Colorectal Neoplasms 136 Carcinoma, Hepatocellular 130 Neoplasms 123 Leukemia, Myeloid, Acute 115 Lung Neoplasms 104 Squamous Cell Carcinoma of Head and Neck 95 Multiple Myeloma 93 Pancreatic Neoplasms 91 Triple Negative Breast Neoplasms 86 Recurrence 85 Stomach Neoplasms 83 Ovarian Neoplasms 83 Neoplasm Metastasis 76 Melanoma 66 Lymphoma, Large B-Cell, Diffuse 66 Esophageal Neoplasms 62 Sarcoma 60 Rectal Neoplasms 60 Brain Neoplasms 60 Uterine Cervical Neoplasms 57 Glioblastoma 57 Precursor Cell Lymphoblastic Leukemia-Lymphoma 56 Head and Neck Neoplasms 56 Carcinoma, Renal Cell 51 Lymphoma 47 Leukemia, Lymphocytic, Chronic, B-Cell 47 Endometrial Neoplasms 47

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡